Clinical Research Directory
Browse clinical research sites, groups, and studies.
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
Sponsor: Juventas Cell Therapy Ltd.
Summary
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Official title: To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2024-06-05
Completion Date
2029-06-05
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Locations (10)
Peking University People's Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Qilu Hospital of Shandong university
Jinan, Shandong, China
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality, China
West China School of Medicine/West China Hospital of Sichuan University
Chengdu, Sichuan, China
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China